

Supplementary:

Table 4: Associations of MPO With Atherosclerosis Phenotypes After Adjustment for Traditional Risk Factors and inflammatory biomarkers

	Prevalent CAC (n=2502)	Prevalent Plaque (n=2287)	APB (n=2287)		AWT (n=2300)	
	OR (95% CI)	OR (95% CI)	Beta coeff	P value	Beta coeff	P value
Model Adjusted for Traditional Risk Factors + TNFR1A						
Log_MPO	0.95 (0.82, 1.1)	1.08 (0.95, 1.21)	0.06	0.20	0.02	0.03
Q1	Reference	Reference	Reference	Reference	Reference	Reference
Q2	0.82 (0.59, 1.14)	1.01 (0.77, 1.32)	-0.09	0.39	-0.02	0.27
Q3	0.78 (0.55, 1.12)	0.97 (0.72, 1.29)	-0.08	0.44	0.004	0.82
Q4	0.75 (0.5, 1.11)	1.35 (0.98, 1.86)	0.20	0.10	0.04	0.06
Model Adjusted for Traditional Risk Factors + MCP1						
Log_MPO	0.98 (0.87, 1.1)	1.09 (0.99, 1.20)	0.06	0.08	0.01	0.03
Q1	Reference	Reference	Reference	Reference	Reference	Reference
Q2	0.86 (0.63, 1.2)	1.03 (0.79, 1.34)	-0.08	0.44	-0.02	0.23
Q3	0.82 (0.59, 1.14)	0.96 (0.74, 1.26)	-0.09	0.38	-0.001	0.97
Q4	0.84 (0.6, 1.17)	1.39 (1.06, 1.83)	0.21	0.04	0.03	0.06
Model Adjusted for Traditional Risk Factors + Osteoprotegerin						
Log_MPO	0.98 (0.87, 1.1)	1.1 (1.003, 1.21)	0.07	0.04	0.01	0.02
Q1	Reference	Reference	Reference	Reference	Reference	Reference
Q2	0.84 (0.61, 1.16)	1.02 (0.78, 1.33)	-0.08	0.41	-0.02	0.24
Q3	0.83 (0.6, 1.15)	0.98 (0.75, 1.28)	-0.08	0.45	0.001	0.96
Q4	0.83 (0.6, 1.15)	1.4 (1.07, 1.83)	0.22	0.03	0.03	0.05
Model Adjusted for Traditional Risk Factors + MMP9						
Log_MPO	0.98 (0.87, 1.1)	1.10 (1.001, 1.21)	0.07	0.05	0.01	0.02
Q1	Reference	Reference	Reference	Reference	Reference	Reference
Q2	0.86 (0.63, 1.19)	1.03 (0.79, 1.35)	-0.07	0.48	-0.02	0.24
Q3	0.84 (0.61, 1.17)	0.998 (0.77, 1.30)	-0.06	0.54	0.002	0.88

Q4	0.84 (0.61, 1.16)	1.04 (0.93, 1.16)	0.23	0.02	0.03	0.04
----	-------------------	-------------------	------	------	------	------

Model Adjusted for Traditional Risk Factors + hsCRP

Log_MPO	0.97 (0.86, 1.09)	1.09 (0.99, 1.2)	0.06	0.08	0.02	0.01
Q1	Reference	Reference	Reference	Reference	Reference	Reference
Q2	0.84 (0.61, 1.16)	1.01 (0.78, 1.32)	-0.09	0.39	-0.02	0.23
Q3	0.83 (0.6, 1.15)	0.99 (0.76, 1.29)	-0.07	0.48	0.004	0.83
Q4	0.81 (0.58, 1.13)	1.37 (1.04, 1.79)	0.20	0.04	0.04	0.03

Model Adjusted for Traditional Risk Factors + SRAGE

Log_MPO	0.97 (0.87, 1.09)	1.10 (1.003, 1.21)	0.07	0.04	0.02	0.01
Q1	Reference	Reference	Reference	Reference	Reference	Reference
Q2	0.85 (0.61, 1.17)	1.03 (0.79, 1.34)	-0.08	0.45	-0.02	0.25
Q3	0.85 (0.61, 1.17)	0.994 (0.76, 1.30)	-0.06	0.54	0.003	0.84
Q4	0.83 (0.6, 1.15)	1.41 (1.08, 1.84)	0.23	0.02	0.04	0.03

Model Adjusted for Traditional Risk Factors + IL18

Log_MPO	0.99 (0.85, 1.12)	1.13 (1.00, 1.28)	0.07	0.14	0.02	0.05
Q1	Reference	Reference	Reference	Reference	Reference	Reference
Q2	0.97 (0.65, 1.46)	1.14 (0.82, 1.6)	-0.03	0.80	-0.03	0.21
Q3	0.96 (0.64, 1.46)	1.11 (0.79, 1.55)	-0.04	0.76	0.002	0.93
Q4	0.93 (0.61, 1.43)	1.6 (1.13, 2.26)	0.26	0.05	0.05	0.03

CAC, coronary artery calcification; APB, aorta plaque burden; AWT, aorta wall thickness; TNFR1A, tumor necrosis factor-alpha 1 receptor; MCP-1, monocyte chemoattractant protein-1; MMP9, matrix metalloproteinase-9; hsCRP, high sensitivity C-reactive protein; SRAGE, soluble receptor for advanced glycation end products; IL18, interleukin-18.